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INDUCTION OF PLURIPOTENCY IN HUMAN KERATINOCYTES THROUGH
mRNA TRANSFECTION. Robert D. Leone, Peter M. Rabinovich, Eugenie Cheng,
Efim Golub, and Sherman M. Weissman. Department of Genetics, Yale University,
School of Medicine, New Haven, CT.
Induced pluripotent stem (iPS) cells are epigenetically reprogrammed somatic cells that
exhibit developmental and proliferative characteristics of embryonic stem (ES) cells.
Other than alterations made during the reprogramming process, iPS cells are
genotypically identical to donor tissue, giving them significant potential in regenerative
medicine, basic biology of genetic disease, and drug development. Presently, iPS cell
derivation largely relies on the introduction of reprogramming factors (eg, OCT4, SOX2,
KLF4, c-MYC) directly into cellular genomes, leaving cells vulnerable to insertional
mutagenesis and persistent expression of oncogenic transcription factors. This severely
limits their use in clinical and research settings. Here we describe the reprogramming of
human keratinocytes through the introduction of exogenous mRNA transcripts. mRNA
presence within cells is transient and is unlikely to have permanent effects on the cellular
genome, thus avoiding the pitfalls of present methods of iPS cell generation. Several
benchmarks have been achieved toward this end, includ-ing: 1) successful expression in
human cells of reprogramming factor proteins through the introduction of exogenous
mRNA transcripts; 2) phenotypic transformation of human keratinocytes toward ES cell
morphology by transfection with mRNA reprogramming factors; and 3) alkaline
phosphatase activity (a well described early marker of pluripotency) in a small proportion
of transformed cells. These results imply that mRNA transfection may be a viable method
for reprogramming somatic cells towards pluripotency.
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BACKGROUND
Human embryonic stem (hES) cells are characterized by two fundamental qualities: the
ability to indefinitely self-renew, and the capacity to differentiate into any and all tissues
of the body. Since first being isolated in 1998, hES cells have been the subject of
significant attention from researchers as well as the lay public (1). Potential applications
of these pluripotent and inexhaustible cells include studies of basic mechanisms of
disease, screens for drug discovery, and the possibility of generating tissue for use in
patients with degenerative diseases such as Parkinson disease, patients in need of bone
marrow transplantation, or patients with infarcted cardiac tissue (2,3,4,5). One limitation
of ES cells, however, is that they are generic in nature, and as such are unrelated to
patients who may be the beneficiaries of such use. Consequently, tissues derived from
hES cell lines will likely be the target of immune rejection in recipients (6,7). Also,
because the only known source of hES cells is the inner cell mass of a human blastocyst,
research into the basic nature and potential application of hES cells has been embroiled in
ethical, religious, and political concerns. Spurred on by both the promise, as well as the
limitations of hES cells, researchers have investigated alternative means of achieving
pluripotency. These investigations have taken the form of nuclear transfer experiments
(8,9), cell fusion experiments between somatic cells and ES cells (10,11), and the design
of transformative cell culture conditions to attain pluripotency in testis cells (12,13).

Somatic cell nuclear transfer (SCNT), wherein a somatic cell nucleus is transplanted into
an oocyte or ES cell and subsequently achieves pluripotency through epigenetic
reprogramming, has been successfully demonstrated in a variety of non-human,
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mammalian species (most notably in “Dolly” the sheep in 1996) (9,14,15). The products
of successful SCNT experiments are pluripotent cells that are identical in genomic
makeup to the starting cell nucleus (14). While this approach would theoretically produce
patient-specific, rejection-proof pluripotent cells for therapeutic and analytical use, it is
limited by several challenges. SCNT technology requires the use of unfertilized oocytes,
which are difficult to obtain. Though it is possible that this limitation may be overcome
by the use of fertilized zygote cells, as was recently shown in the mouse, SCNT is also a
very technically challenging and inefficient technology that is not at present viable for
routine use in the clinic (16).

Despite limitations, SCNT experiments have shown unequivocally that cellular
differentiation is not necessarily a one-way street. By exposing a somatic nucleus to the
appropriate cytocellular environment (oocyte or ES cell), epigenetic reprogramming is
facilitated and pluripotency established. In the last several years, researchers have applied
these concepts as they have attempted to more fully understand the specific elements
present in oocytes and ES cells that affect nuclear reprogramming and maintain
pluripotency. By carefully sifting through data examining transcription factors present in
ES cells, researchers were able to identify a set of four such factors that were sufficient to
reprogram somatic cells to pluripotency. In a biomedical milestone reported in 2006,
Takahashi and Yamanaka successfully reprogrammed murine embryonic fibroblasts to
de-differentiated states of pluripotency using retroviral insertion of gene sequences of
four transcription factors: Oct4, Sox2, Klf2, c-Myc (7). These cells have been termed
“induced pluripotent stem cells” (iPS cells). These results were extended to the
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reprogramming of human fibroblast cells in the laboratory of James Thompson in 2007
using retroviral insertion of gene sequences for OCT4, SOX2, NANOG, and LIN28 (17).
In the last few years iPS cells have been derived by various researchers from several
different human cell types including keratinocytes, hematopoietic cells, cord blood, and
hair follicle cells (18, 19, 20, 21).

Though the precise criteria for pluripotency is the subject of ongoing debate (22), iPS
cells have been shown to be similar to embryonic cells in several important ways (23,
24). iPS cells show significant similarity to ES cells morphologically, epigenetically, and
in their expression of key ES cell marker genes. iPS cells also demonstrate other
important characteristics of pluripotency, including the ability to form teratomas when
injected into mouse testes, the ability to contribute to tissues of adult chimeric mice that
are germline competent, and the ability to form all tissues of a viable organism through
tetraploid complementation assays (23, 24, 25). Though the most stringent of these
assays—chimera formation and tetraploid complementation—are not ethically available
for work involving human iPS cells, these cells have been successfully induced to form
teratomas comprising three primary germ cell layers and have been subjected to several
differentiation schemes to form specific human tissues, such as cardiomyocytes,
hematopoietic stem cells, osteoclasts, hepatocytes, and neurons (18, 23, 24, 26, 27, 28,
29).

The ability to reprogram somatic cells to pluripotency has led to great excitement in the
field of stem cell research and regenerative medicine. These reprogrammed somatic cells
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have several important advantages over ES cells in biomedical application. First, iPS cell
technology avoids ethico-religio-political complexities that have bridled embryonic stem
cell research for much of the last decade. Second, iPS cells are derived in a patientspecific manner, and so, organs and tissue derived from these cells are likely to avoid
immune rejection that would otherwise complicate application in regenerative medicine.
Third, the patient-specific nature of iPS cells allows for the observation of developmental
irregularities that are likely inherent in many disease states. For example, iPS cells
derived from individuals with Parkinsons Disease or ALS can be differentiated into
dopaminergic neurons and monitored developmentally for insight into sequential
pathologic aberrations inherent in the disease process (30, 31, 32). Lastly, this technology
holds great promise for evaluating medication-induced abnormalities in a tissue-specific,
patient-specific manner. That is, although the nature of the toxicity of a particular drug
on heart tissue may theoretically be ascertained by studies on cardiomyocytes derived
from ES cells, the results could not take into account phenotypic and functional
polymorphisms that may present in a given individual. iPS cell derivation could allow
such tailored study (33).

Despite the enormous promise of iPS cell technology, the field is presently limited in
clinical application due to the manner of iPS cell derivation. Present methods of somatic
cell reprogramming rely largely on viral vectors to introduce genetic material
permanently into the genome. Inserted genetic material includes both the viral backbone,
as well as transgene sequences coding for the transformative factors (OCT4, SOX2,
KLF4, c-MYC, NANOG, LIN28) (7,17). Such an approach engenders several significant
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pitfalls that at present limit clinical application. First, virally introduced material can
produce insertional mutagenesis, disrupting the normal function of endogenous genetic
material and leading to unintended phenotypes and possibly malignant transformation
(34). Mutagenetic effects may also have significant effects on the differentiation potential
of established iPS cells. Second, inserted transgenes may continue to be active after
pluripotency has been established. This may also have implications for the differentiation
potential of iPS cells, but, perhaps more importantly, has the potential to activate a
tumorigenic phenotype, which is especially concerning considering the association of
several of the induced factors (c-MYC, KLF4) with malignant transformation (17, 35).

In order for the full promise and clinical viability of iPS technology to be realized,
pluripotency must be achieved by means that minimize or eliminate unanticipated and
undesired phenotypes such as malignant transformation. This problem has been
approached by several researchers in a variety of ways, including using adenoviruses or
episomal vectors to provide nonintegrating transfer of genetic material (36, 37),
Cre/LoxP recombination and Piggy-Bac technology to remove inserted genetic material
after cellular transformation has been achieved (38, 39, 40), and protein-based schemes
have been reported. Unfortunately these approaches also have significant drawbacks that
limit their usefulness in the clinical setting, including very low yield, long turn-around
time, and complicated procedures. In addition, many of these approaches continue to rely
on the introduction of exogenous DNA into host cells, failing to completely remove the
possibility of genetic recombination at the level of the genome. Post-transformation
excisional schemes using Cre/LoxP recombination has the additional limitation of
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imprecise excision of integrated transgenes, thus failing to circumvent concerns of
insertional mutagenesis. The use of DNA constucts, such as episomal material, for
transient transfection is problematic because of the inherent toxicity of DNA which limits
the concentration range that can be used effectively (41). DNA also requires nuclear entry
which is limited in some cell types (41). Such methods can also lead to low-frequency
integration into host genome (42).

In an attempt to address many of the limitations of current procedures in deriving human
iPS cells, we have investigated the viability of using mRNA transfection of somatic cells
to induce pluripotency. The most important aspect of this approach lies in the fact that
mRNA, unlike DNA, is unlikely to have a permanent effect on the cellular genome.
mRNA is completely and irreversibly degraded, eventually leaving transfected cells
absent of any transgene expression. Also, translation of mRNA into protein, unlike DNAbased methods, does not require nuclear entry. Rabinovich et al. have recently developed
a fast and effective approach for in vitro synthesis of mRNA that can be introduced into
human cells (41). These studies showed that mRNA transfection of human cells can be
achieved at efficiencies much higher than that of DNA transfection, with a more uniform
introduction of material across cell populations. This approach has successfully been
employed to reprogram different types of primary cells and cell lines, including T
lymphocytes, NK cells, B cells, and several cancer cell lines. T lymphocytes, and natural
killer cells have been reprogrammed with chimeric immune receptor (CIR) constructs
that direct these cells towards various surface targets (43). For example, by using antiCD19 CIR and anti-8H9 CIR, a variety tissue types have been targeted by the
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reprogrammed killer cells, including B cells, Daudi lymphoma, primary melanoma,
breast ductal carcinoma, breast adenocarcinoma, and rhabdomyosarcoma (43). In the
present study we have adapted these methods of mRNA transfection to develop an
approach for the reprogramming of somatic cells to pluripotent states.

Recently, many researchers have addressed the poor efficiency and slow kinetics of iPS
cell generation. Various methods have been successful in this regard. First, the choice of
starting cell type bears heavily on the speed and efficiency of the reprogramming process.
Although fibroblasts have been the standard starting tissue for most iPS cell studies,
several investigators have reported that keratinocytes reprogram faster and more
efficiently in both mouse and human systems (18, 44). There have also been mouse
studies showing that early progenitors and hematopoietic stem cells are more easily and
more quickly reprogrammed than more well-differentiated hematopoietic cells (45).
Second, small molecule epigenetic modifying factors, such as valproic acid (histone
deacetylase inhibitor) and 5’-azacytidine (DNA-hypomethylating agent), have also been
shown to enhance the success of reprogramming (46). It is thought that these agents aid
in the chromatin remodeling that must occur to produce fully transformed cells. Valproic
acid has been shown to increase efficiency of reprogramming up to 40 times and has
allowed reprogramming with the use of only two exogenous factors, OCT4 and SOX2
(46, 47). Third, recent studies have demonstrated that knock-down of P53 activity can
enhance reprogramming. The process of reprogramming has been shown to activate the
P53 pathway which in turn acts as a barrier to full reprogramming (48, 49). Lastly, the
use of five factors (OCT4, SOX2, KLF4, c-MYC, NANOG) instead of the standard four
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factors has shown promise in increasing yield and kinetics of iPS cell formation,
especially in systems that do not employ retroviruses as the means of reprogramming (37,
50).

In the present work, we have optimized mRNA electroporation protocols for
keratinocytes, performed in vitro mRNA synthesis of factors required for iPS
reprogramming (OCT4, SOX2, KLF4, c-MYC, and NANOG) and demonstrated that,
upon transfection, these transcripts produce detectable protein. In an effort to optimize
the yield of transformed cells, we have also synthesized a truncated form of P53, known
as P53DD, which has been shown to have a dominant negative effect on P53 activity in
human cells (49, 51). We have investigated the capacity of both human keratinocytes and
human fibroblasts to transform under various conditions, including 4 and 5 factor mRNA
transfection, in the presence of valproic acid, and with concomitant transfection with a
P53 dominant negative construct. The presence of iPS cell generation has been assessed
by the presence of alkaline phosphatase activity of formed colonies, which is well known
as an early marker of pluripotency. We have observed the generation of a small number
of alkaline phosphatase-positive cells by electroporating human keratinocytes with
OCT4, SOX2, KLF4, c-MYC, and NANOG.
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MATERIALS AND METHOD
Cell Culture. Neonatal human epidermal keratinocytes (nHEK) and nenotal human
foreskin fibroblasts (nHFF) were obtained from the Yale Cell Culture Core Facility.
Keratinocytes were cultured in serum-free low calcium medium (Epilife, Invitrogen);
fibroblasts were cultured in DMEM medium in 10% heat-inactivated fetal bovine serum
(Gibco). For viral reprogramming, keratinocytes, passage 5-6, were infected with a
1:1:1:1 mix of retroviruses with OCT4, SOX2, KLF4, and c-MYC in the presence of
1µg/ml polybrene and centrifuged for 45 minutes at 750g on 2 consecutive days. For
reprogramming with mRNA constructs, keratinocytes were electroporated with mRNA
transcripts corresponding to reprogramming factors as described below. For initial
experiments mRNA corresponding to each of four transcription factors (OCT4, SOX2,
KLF4, c-MYC) were used in a 1:1:1:1 ratio respectively. For experiments using high
OCT4 concentrations, the same four factors were used in a 3:1:1:1 ratio. For experiments
using the initial four factors plus either NANOG or P53DD, the five mRNA transcripts
were present in a ratio of 1:1:1:1:1. After viral infection or electroporation, keratinocytes
were grown in fresh serum-free, low calcium medium at 37C and 5% CO2 for 2 days,
after which they were trypsinized and seeded onto multi-well plates containing irradiated
mouse fibroblasts. Transfected cells were seeded 2.5 x 106 cells/cm2 and cultured with ES
cell medium (DMEM/F12 containing 20% KOSR (vol/vol), 5–10 ng ml- 1 bFGF, 1 mM
L-GIn, 100 M nonessential amino acids, 100 M 2-mercaptoethanol, 50 U ml- 1
penicillin and 50 mg ml- 1 streptomycin). Neonatal human foreskin fibroblasts were used
to confirm the expression of individual mRNA constructs of the various reprogramming
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factors and were cultured in DMEM with 10% heat inactivated fetal bovine serum. All
cell culture procedures were carried out by Robert Leone.

Retroviral production. Following the method of Park, et al., retroviruses containing
OCT4, SOX2, KLF4, and c-MYC were formed using pMIG vectors (Addgene) which
also contained sequence for GFP expression (52). The production of retroviruses was
carried out by Eugenie Cheng in the laboratory of Haifan Lin.

RNA synthesis. As described in Rabinovich et al. (41, 43), green fluorescent (GFP)
mRNA constructs were produced in vitro with T7 polymerase and were based on the
Pontellina plumata GFP sequence of plasmid pmaxGFP (Amaxa Biosystems, Cologne,
Germany) (41,43). OCT4, SOX2, KLF4, c-MYC, P53DD, and NANOG constructs were
created by replacing the GFP coding region in pmaxGFP with the appropriate open
reading frame from each gene. DNA templates were produced by polymerase chain
reaction (PCR) using AccuPrime Pfx DNA polymerase (Invitrogen) according to
manufacturer’s protocol. Twenty-five to 30 cycles of PCR were performed in a standard
50-µl reaction using 0.1 mg of template DNA. The forward primer contained the T7
RNA promoter and an anchoring sequence in the proximal part of the gene expression
cassette. The reverse primer, with anchoring sequence in the distal part of the gene
expression cassette, contained a stretch of 100 dT residues. Design of DNA inserts for
OCT4, KLF4, SOX2, c-MYC, and NANOG was carried out Peter Rabinovich. Design of
the DNA insert sequence for the P53 dominant negative construct (P53DD) was carried
out by Robert Leone. PCR was carried out by Efim Golub.
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mRNA synthesis with T7 RNA polymerase has been described by Rabinovich et al. (41,
43). This was performed with an mMESSAGE mMACHINE T7 Ultra kit (Ambion,
Austin, TX), using the procedure recommended by the manufacturer. One hundred to 200
ng of DNA made by PCR with no further purification was used for the standard 20-µl
transcription reaction. The product was treated with Escherichia coli poly(A) polymerase
(from the same kit) in the presence of 1mM ATP according to the Ambion
polyadenylation protocol. The yield of mRNA was 20 to 60 mg of mRNA per reaction.
The final product was treated with DNase I (Ambion) and purified by LiCl precipitation.
RNA was stored at -80C. mRNA production was performed by Robert Leone.

mRNA transfection of human cells
Electroporation of human keratinocytes and fibroblasts.
Electroporation was performed with an Amaxa Nucleofector II (Amaxa, Gaithersburg,
MD) in accordance with manufacturer recommendations. Keratinocytes were
electroporated with ‘‘Human Keratinocyte Nucleofector Kit Solution’’ and programs
T007, T018, and T024. Human fibroblasts were electroporated with ‘‘Human Dermal
Fibroblast Nucleofector Kit Solution’’ using program U020. For GFP transfection
experiments, keratinocytes were electroporated with DNA (20µg/ml) or mRNA (30200µg/ml) per sample. Cells were used at a concentration of 10–250 million/ml. In this
interval of values the efficiency of transfection does not depend on cell density
(Rabinovich et al., 2006). The efficiency of transfection was determined by flow
cytometry 18 hours after transfection. Cell viability post-transfection was assessed by
tryptan blue staining hemocytometry. In standard reprogramming experiments, OCT4,
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SOX2, KLF4, and c-MYC were used in a 1:1:1:1 ratio with 30µg/ml final concentration
of each factor. In experiments containing high OCT4, a 3:1:1:1 ratio was used. In
experiments using NANOG, a 1:1:1:1:1 ratio (OCT4:SOX2:KLF4:c-MYC:NANOG) was
used. In experiments using P53DD (P53 dominant negative construct), a 1:1:1:1:1 ratio
(OCT4:SOX2:KLF4:c-MYC:P53DD) was used. All electroporation procedures reported
on in this work was performed by Robert Leone.

Cationic liposomal transfection of human keratinocytes and fibroblasts.
Cationic-liposomal transfection experiments were carried out using the TransIT®-mRNA
Transfection Kit (Mirus). Conditions were optimized for keratinocyte and fibroblast
transfection according to the manufacturer’s recommendations using both GFP plasmid
as well as GFP mRNA transcripts produced by the above methods. Transfection of both
keratinocytes and fibroblasts was performed in cell culture conditions on a feeder layer of
irradiated mouse embryonic fibroblasts as described above. Optimization of transfection
conditions for keratinocytes was performed by Robert Leone. Optimization of
transfection conditions for fibroblasts was performed by Eugenie Cheng. Mirus
transfection experiments using reprogramming factors was carried out by Eugenie Cheng.

Flow Cytometry. Flow cytometric analysis of cell subpopulations was performed at the
Yale Cancer Center Flow Cytometry Shared Resource (New Haven, CT), using a
FACSCalibur (BD Biosciences). Fluorescence signals were collected using a 488-nm
laser on a logarithmic scale. Unless otherwise noted, at least 10,000 events were acquired
for each sample. Data were analyzed with FlowJo software (TreeStar, Ashland, OR).
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Flow cytometric analysis was carried out by Robert Leone with assistance from Eugenie
Cheng and Peter Rabinovich.

Electrophoresis. All protein expression assays were performed on cell lysates from
transfected neonatal human foreskin fibroblasts, passage 7-12. In the presence of protease
inhibitors, whole cell extracts were obtained by lysis using either RIPA buffer and
standardized against untransfected control cells using BCA protein quantitation (c-MYC,
NANOG, P53DD) or laemmli buffer and standardized against untransfected controls by
cell concentration measurement (KLF4, SOX2, OCT4). Protein extracts were analyzed
by Western blot analysis using specific antibodies against c-MYC (StemGent 09-0032 at
1:100 dilution); NANOG (Abcam ab80892 at 1:100 dilution); P53 (Calbiochem Pab421
at 1:10 dilution), KLF4, SOX2, OCT4. Alkaline phosphatase-conjugated goat anti-mouse
antibody (sc-2005, Santa Cruz) and goat anti-rabbit antibody (sc-2004, Santa Cruz) were
used as secondary antibodies at 1/500-1/2000 dilution range. Blots were developed using
SuperSignal West Pico Chemiluminescent Substrate System (Pierce). Electrophoresis
analysis of OCT4 and SOX2 was performed by Eugenie Cheng. All other electrophoresis
experiments were performed by Robert Leone.

Alkaline phosphatase analysis. Direct alkaline phosphatase (AP) activity was assessed
using Alkaline Phosphatase Staining Kit (Stemgent, Inc, Cambridge, MA) according to
the manufacturer’s recommendations. Alkaline phosphatase analysis was performed by
Robert Leone.
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RESULTS
mRNA and DNA transfection. Transfection experiments were performed on human
neonatal keratinocytes and fibroblasts. Keratinocytes have been reported to reprogram to
iPS cells with faster kinetics and greater efficiency than human fibroblasts (18, 44). In
unpublished data from our lab (Peter Rabinovich), it was demonstrated using rt-PCR that
GFP mRNA transcripts maintain a half-life of approximately 4-5 hours in human
lymphocytes, leaving only 10% of material after 15 hours. Because transfected mRNA
transcripts are transient in cells and because translated proteins are diluted two-fold with
each cellular division, the kinetic advantage of keratinocytes in reprogramming was
thought to be an important attribute of our system. mRNA transfection was attempted by
both electroporation using the Amaxa Nucleofector II as well as the Mirus system of
cationic liposome-mediated transfection. To determine optimal electroporation
parameters using Amaxa Nucleofector II, we first transfected keratinocytes with a green
fluorescent protein (GFP) reporter gene from Pontellina plumata, using mRNA and DNA
transgenes. Using keratinocyte electroporation solution proprietary to Amaxa we tested
several electroporation protocols and determined that Nucleofector II program T-024
gave the highest efficiency of transfection when assessed by geometric mean (fig. 1).
Transfection experiments using liposomal reagents on cells in fibroblast and
keratinocytes in cultures were assessed by similar methods and attained similar
efficiencies of transfection (data not shown).

To assess the functionality of mRNA transcripts, transcripts for OCT4, SOX2, KLF4, cMYC, P53DD, and NANOG were individually transfected into neonatal human foreskin
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fibroblasts. Protein synthesis was assessed by Western blot analysis as shown in figure 2.
Upon transfection each transcript allowed for significant protein production compared
with untransfected control fibroblasts. (Sample quantities were standardized by
determining pre-lysis cell quantity or by protein quantitation of cell lysates by
bicinchoninic acid (BCA) protein assay). In all cases protein synthesis was evident above
levels of untransfected control samples. Western blot analysis for NANOG showed
detectable protein in untransfected controls fibroblasts. This is in concordance with a
recent report of low-level basal NANOG expression in human fibroblasts (53).

Introduction of pluripotency factors into keratinocytes and fibroblasts.
Introduction of reprogramming factors using mRNA retroviruses.
For preliminary studies, retroviral transfection was performed to induce pluripotency in
keratinocytes according to published methods (18, 52). Using a 1:1:1:1 mixture of
retroviruses containing reprogramming factors (OCT4, SOX2, KLF4, c-MYC),
keratinocytes (passage 5) were infected twice, 24 hours apart. Two days after the last
infection, cells were trypsinized and seeded onto a feeder layer of irradiated mouse
embryonic fibroblasts (iMEFs) in embryonic stem (ES) cell medium. Expression of
retrovirally inserted genes was assessed by fluorescent microscopy and flow cytometric
analysis of GFP expression one day post transfection. (fig. 3a-c) The fraction of cells
expressing reprogramming factor ranged from 15% to 78% among the four samples.
Despite rather low expression rates, induction of pluripotency was evidenced by
formation of three colonies displaying typical ES cell morphology, each of which was
positive for alkaline phosphatase activity, an early marker of pluripotency (fig. 3d).
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Introduction of reprogramming factors by mRNA transfection.
Using optimized conditions, keratinocytes were transfected with mRNA transcripts
coding for reprogramming transcription factors. Initially, keratinocytes were
electroporated with OCT4, SOX2, KLF4, and c-MYC mRNA transcripts (day 0). After
transfection, cells were grown in keritinocyte medium for 2 days without a feeder cell
layer. On day 2, cells were trypsinized and moved to iMEF feeder cell layers in multiwell plates at a density of approximately 5000 cells/cm2. Medium was changed to ES cell
medium on day 3 after transfection. Thereafter, cells were grown in ES cell medium with
or without 10 mM valproic acid (VPA) supplement. Medium was changed every other
day. Two control populations of keratinocytes were treated to the same culture
conditions, again with and without VPA. Transfected keratinocytes began to show
evidence of transformation on day 4, at which time small colonies began to form that
were particularly abundant in VPA-containing cultures. The colonies were tightly packed
and mostly circular with relatively smooth edges (fig. 4b,d), bearing significant
morphologic similarity to both human embryonic stem cell colonies as well as virally
induced iPS cell colonies (fig. 4a). There were approximately 10-15 colonies/cm2 in
VPA-containing culture conditions and 6-10 colonies/cm2 in cultures without VPA, and
the rate of growth of individual colonies appeared to be slightly higher in VPAcontaining conditions. However, the morphology of the colonies was not appreciably
different between culture conditions (with or without VPA; fig. 4b,d). No colonies were
observed in control cell cultures (no mRNA transfection performed) in either the
presence or absence of VPA (fig. 4c,e). Colonies were assessed for pluripotency by
determining alkaline phosphatase activity at day 10 and day 14. Colonies failed to show
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alkaline phosphatase activity in this initial experiment. Human fibroblasts were
transfected using a similar protocol, but showed no evidence of colony growth in either
VPA treated or untreated culture conditions (data not shown). It was observed that
keratinocytes survived the above transfection relatively poorly, demonstrating a viability
only of about 3 percent.

We also attempted serial transfections of reprogramming factors into human
keratinocytes using a liposomal delivery of mRNA transcripts. Three transfections were
carried out on days 0, 3, and 6 on keratinocytes cultured on irradiated mouse embryonic
fibroblast feeder cells. While cellular transformation was again achieved in a manner
similar to results reported for electroporation experiments described above, all colonies
were alkaline phosphatase negative (data not shown). Using GFP mRNA, it was
discovered that keratinocytes were actually resistant to transfection of mRNA material
after the initial transfection at day 0 (data not shown).

In subsequent experiments several additional approaches were attempted to affect
successful transformation to pluripotency. In published reports, addition of NANOG to
OCT4, SOX2, KLF4, and c-MYC increased the efficiency and the kinetics of
reprogramming in human and mouse fibroblasts. This has been shown in both retroviral
as well as episomal systems of transformation (37, 50). Particularly interesting about this
approach is that the addition of NANOG seems to increase the kinetics of reprogramming
in a fashion that is relatively independent of cellular proliferation rates (50). This is
especially applicable to our system since mRNA transcripts in our system, unlike mRNA
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produced from retrovirally-integrated genes, are not being actively produced or
replenished by the cell during reprogramming. Thus, in addition to the loss in
cytoplasmic mRNA concentration due to normal cellular control mechanisms, transcripts
are diluted by half with each population doubling. NANOG mRNA was synthesized in
vitro as described for the other four factors. Using Western blot analysis, we confirmed
expression of NANOG protein by a transfection experiment using nHFF cells (fig. 5).
The immunoblot showed increased levels over untransfected nHFF cells, however the
evidence of endogenous NANOG expression in control sample was unexpected and
likely due to contamination or nonspecific staining. In an attempt to induce pluripotency,
nHEK cells were transfected with OCT4, SOX2, KLF4, c-MYC, and NANOG in a
1:1:1:1:1 ratio. In culture conditions without valproic acid (VPA), small colonies began
to become evident on day 4 post-transfection. Two of these colonies showed steady
growth over the first 11 days post transfection after which time their size stabilized.
These colonies appeared smaller than colonies formed from the four factors alone,
however they shared their general morphological attributes, being round with distinct
borders. (No colonies were evident in culture conditions containing 1 mM valproic acid.)
Cells were stained for alkaline phosphatase activity. We observed two alkalinephosphatase positive cells that were round with smooth cell borders, distinct from both
native keratinocyte morphology, as well as fibroblast morphology of the feeder layer
cells (fig. 6). Beyond these findings of individual cells, cell colonies in this sample
showed no alkaline phosphatase activity. Approximately 9 x 104 cells were plated in one
well of a 24-well plate to achieve these results.
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In another approach, we took advantage of recent reports showing that the stoichiometry
of the expression of the four factors plays a role in optimal cellular transformation to
pluripotency (54). Specifically, Papapetrou et al. have shown that reprogramming human
fibroblasts to iPS cells is highly sensitive to levels of OCT4 and is optimized when the
four proteins are present intracellularly in a ratio of 3:1:1:1 (OCT4:SOX2:KLF4;cMYC). Accordingly, we transfected nHEK cells with the mRNA of the four factors in
precisely this ratio. In both VPA-positive and VPA-negative culture conditions, cellular
transformation was noted, showing one large colony per well, and many small round
colonies that began to appear at day 4 post-transfection. These were similar in appearance
to those produced through four factor transfection pictured in figure 4. On day 16 posttransfection, these colonies were stained for alkaline phosphatase activity as described.
There was no significant alkaline phosphatase activity above negative control cells of
untransfected nHEK.

Lastly, there have been several reports of the increased efficiency of reprogramming in
the setting of P53 knockdown through use of either shRNA or a P53 dominant negative.
P53 activity was more completely inhibited using a P53 dominant negative construct
consisting of the first 14 N-terminus codons plus the C-terminus 302-390 originally
described by Shaulian et al. (55). We synthesized this construct (P53DD) and confirmed
expression by immunoblot analysis (fig. 5) with a primary antibody directed against the
carboxy terminus of P53 (Pab421, Calbiochem). nHEK cells were transfected with
OCT4, SOX2, KLF4, c-MYC, and P53DD in a 1:1:1:1:1 ratio. Very small colonies began
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to appear on day 4 post-transfection. In contrast to experiments using the four factors and
either NANOG or high OCT4 levels, these colonies remained very small without
noticeable growth. Staining for alkaline phosphatase was done and yielded no significant
results above negative control cells. There was no observable difference between VPApositive and VPA-negative culture conditions.

Assessing keratinocyte viability in mRNA electroporation experiments. In carrying
out the above experiments, it was observed that there was significant loss of cell viability
after each mRNA transfection of keratinocytes. Cell loss ranged from 96-98% in
experiments using all four factors, which used a total mRNA concentration of 120-150
µg/ml. This was significantly more than control keratinocytes that were electroporated
without any mRNA in the transfection solution and which showed a more modest 60%
loss in viability. It had previously been reported that mRNA showed very little toxicity
in the electroporation of various other human cell types, including lymphocytes,
fibroblasts and monocytes (41, 43, 64). The experiments described in these reports used
mRNA at levels approximately equal to those used in our experiments. Initially, it was
unclear whether the significant toxicity observed in our experiments was secondary to
high mRNA levels or to the effect of the expression of the reprogramming factors
themselves. To investigate this further, we compared viability data from nHEK
electroporation experiments using increasing concentrations of GFP mRNA, expression
of which has been previously shown not to be toxic in human cells (41, 43). We
compared three groups of nHEK cells, including cells undergoing electroporation with no
mRNA present, and two groups of cells electroporated with 30 µg/ml and 200µg/ml of
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GFP mRNA respectively. Post-transfection all cells were incubated overnight in
keratinocyte medium, after which they were trypsinized and anaylized for cell viability
by manual counting with a hemocytometer (fig. 7). Data from this experiment show that
increasing concentrations of GFP mRNA is toxic to human keratinocytes.
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DISCUSSION
The use of retrovirally introduced transcription factors has been exceptionally and
reproducibly successful as a general approach to the induction of pluripotency in somatic
cells. We are indebted to researchers using these methods in the inception and early
development of the field iPS cell technology. Beginning with the revelatory work of
Yamanaka, the use of retroviruses to introduce transformative factors has produced great
advances in our understanding of the capacity for differentiated cells to adopt pluripotent
states. Using these methods researchers have unlocked the ability of somatic cells to be
transformed into many tissues of the body, including cardiomyocytes, hematopoietic stem
cells, osteoclasts, hepatocytes, and neurons (18, 23, 24, 56, 57, 58, 59). Researchers have
also been successful in correcting genetic mutations in iPS cells derived from patients or
mouse models with genetic mutations causing Duchenne muscular dystrophy,
hemophilia, and sickle cell anemia, and subsequently differentiated these cells into
disease-free phenotypes (60, 61, 62, 63). Work has also been accomplished, using similar
methods of viral transformation, in transdifferentiating between somatic cell types, such
as transforming pancreatic exocrine cells into insulin-producing beta islet cells (64).
Importantly, all of this work has been accomplished—much of it in human systems—
without the specter of ethical suspicion or political-legal regulation hindering advances.
Indeed, the advances that have already been uncovered, along with the promise of things
to come are truly historic and will likely have implications on many aspects of society.

Holding at bay future promise from becoming accepted advances, however, are current
limitations of the technology of virally induced genetic material that has, to this point,
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brought the field so far in such a short time. Insertional mutagenesis, transgene
reactivation, and oncogenic transformation are all serious pitfalls in any reprogramming
technology using DNA as the transformative element, especially those employing
retroviruses. The potential of using mRNA transfection technology to induce
pluripotency is an important advance in removing these last hurdles before clinical
application of iPS technology.

In the current work we have accomplished important steps toward fulfillment of this goal.
We have successfully synthesized mRNA constructs corresponding to the transformative
factors OCT4, SOX2, KLF4, c-MYC, and NANOG and demonstrated their expression
individually in human fibroblasts. We have also demonstrated that these factors can be
used reproducibly to affect cellular transformation of human keratinocytes in culture.
Lastly, although the efficiency was low, we have observed the presence of two alkalinephosphatase-positive cells through keratinocyte reprogramming with OCT4, SOX2,
KLF4, c-MYC, and NANOG in the absence of valproic acid. It remains to be seen if
these cells are capable of forming viable colonies. The pluripotent potential of cells
transformed in this way will be investigated in future work. Evaluation of expression of
other markers of pluripotency markers such as SSEA-4, SSEA3, TRA-1-60, TRA-1-81
will be very important, as well as assessing the potential of these cells to form teratomas
or differentiate into other somatic cell types by known methods.

We believe the most significant advantage of our approach—the transient nature of
intracellular mRNA—is also its most challenging limitation. Previous experiments
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showed GFP protein expression up to 2 weeks post-electroporation in human cells
(unpublished data, Peter Rabinovich). However, in our examination of protein expression
of OCT4 and SOX2 in mRNA-transfected human fibroblasts, transgene proteins were
expressed for less than 6 days post-transfection (data not shown). Previous studies
investigating the kinetics of reprogramming have found that at least 7 days of transgene
expression is necessary for pluripotent transformation. We have attempted to address this
issue by using approaches that have been reported to increase the kinetics of
reprogramming, including the use of the four standard factors plus either NANOG or
knockdown of P53 activity. (Our choice of keratinocytes as starting cells, which have
been reported to have faster reprogramming kinetics, was also made with this in mind).
Though it appears that the use of four factors plus NANOG has improved the
reprogramming process (as evidenced by the generation alkaline-phosphatase positive
cells), the efficiency of the process must be further optimized. This limitation may be
further addressed in one of several ways. One approach would be to increase the half-life
of mRNA in cells. It is possible that this could be achieved using constructs from
negative RNA viruses, such as the Sendai virus, which enable the replication of mRNA
strands in mammalian cytosol. Our lab is presently investigating the viability of this
approach in several systems. Another approach would be to investigate the viability of
repeated transfections of reprogramming factors performed in the course of cellular
transformation. A similar approach was successfully implemented by Zhou et al. who
achieved pluripotent transformation using recombinant protein reprogramming factors
(65). In the present study we attempted serial transfections using a cationic-liposomal
method. Using this approach, which allows for in situ transfection of cells in culture, we
found that keratinocytes were unable to be transfected once they were exposed to ES

30
culture conditions (data not shown). While the reason behind this recalcitrance is unclear,
it may be possible that optimization of transfection medium during reprogramming could
produce a more favorable environment for transfection (66). While multiple
electroporations of keratinocytes was an untenable idea in our present system considering
the extremely low cell viability using the Amaxa Nucleofector II, there are other
approaches to electroporation which may allow the possibility of multiple in situ
transfections of these adherent cells (67, 68).

An unexpected finding in our study was that of the apparent toxicity of high levels of
mRNA on keratinocytes during electroporation. The implications of this finding are
unclear at present. Several previous reports, including work done in our lab, had
uncovered no toxic effect of similar levels of mRNA (GFP) on mammalian cells,
including human fibroblasts, lymphocytes, peripheral blood mononuclear cells, and
murine splenocytes (41, 43, 69). In these studies, the subsequent expression of GFP
protein was also not found to be toxic to these cells. This led us to speculate that it was
the increasing concentration of mRNA itself that was toxic to keratinocytes. It is known
that keratinocytes are subject to a phenomenon known as the “ribotoxic stress response.”
This response involves the activation of stress-activated protein kinases (SAPK) and is
typically triggered by damage to ribosomal RNA by toxins, antibiotics, UVB radiation, or
other cellular stressors. Interestingly, the SAPK cascade, which often results in cellular
apoptosis, can only be triggered by ribosomes that are actively translating (70, 71, 72). It
is possible that such a mechanism, wherein cell death is correlated to the intensity of
protein synthesis, may be involved in the results we have observed. That is, as a higher
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concentration of mRNA is introduced into cells and translational machinery is more fully
engaged, all during the stress of electroporation and concomitant recovery, cells become
more highly susceptible to the mechanisms of ribotoxic stress response. Future
investigations should be made into the benefit of delaying protein translation for some
amount of time after electroporation. This could be accomplished by the use of a
reversible inhibitor of protein biosynthesis such as cyclohexamide. If keratinocyte cell
death is in fact related to the degree of ribosomal activity, a delay of such activity until
after cellular recuperation might lessen the effect. Whatever the mechanism of cell death,
it is clear that the electroporation process is selecting for a rather small subpopulation of
keratinocytes. Whether these surviving cells are more or less likely to be reprogrammed
is not known. The fact that they have demonstrated morphological transformation and
some evidence of alkaline-phosphatase activity is quite encouraging, however. In the
future, the issue of poor cell viability may be addressed by decreasing mRNA
concentration in electroporation experiments, as well as investigating alternative
transfection procedures. Using keratinocytes at lower passage number may also increase
the health and subsequent viability of these cells.

Future work on this project will be directed in several directions. First, effort will be
directed towards more fully elucidating the nature of the transformed cell colonies that
have been produced from the reprogramming of keratinocytes in this work. Because of
the poor cell viability after electroporation with mRNA, we did not have sufficient cells
from experiments that produced alkaline-phosphatase activity to apply more stringent
pluripotency assays. This will be of foremost importance in future work. The important
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question is whether these cells (as well as cells that have been morphologically
transformed and do not show alkaline phosphatase activity) show any further
characteristics of pluripotency. This can be done by comparing molecular markers such
as epigenetic patterns of CpG methylation and histone acetylation on promoter regions of
key pluripotency genes such as OCT4 and NANOG. Microarray data could also be
obtained and compared between transformed cells, iPS cells, ES cells, and known
malignant phenotypes of keratinocytes. RT-PCR experiments would also be valuable in
determining precise levels of transcripts that are known to be associated with
pluripotency (SSEA-4, SSEA3, TRA-1-60, TRA-1-81), as well as levels of transcripts
that specifically indicate a differentiated keratinocyte phenotype. Second, increasing the
half-life of mRNA in cells will be an important step towards more effective
reprogramming. This work is presently being engaged in our lab with emphasis on
uncovering proteins or nanoparticles which have the ability to stabilize ectopic mRNA.
As mentioned above, strategies that allow for repeated in situ transfections would be
useful in prolonging the presence of mRNA and expressed protein factors in cells. Third,
there will be continued effort directed toward improving the kinetics of reprogramming in
our system. Possible approaches include using additional transformative factors such as
Lin28, which has been shown to increase rate and efficiency of iPS cell formation (44).
Lastly, using alternative starting cell populations may also allow faster and more efficient
reprogramming. A recent study by Eminli et al. et al showed that less differentiated cells
of the hematopoietic system are more amenable to reprogramming than mature cells (45).
A trial using CD34+ cells as a starting population, for instance, would be an interesting
experiment. In our experience, keratinocytes appear to be unusual in their sensitivity to
high mRNA concentrations during electroporation. As such, we believe that cell types

33
other than keratinocytes will likely not encounter similar problems with postelectroporation viability.
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Figure 1. Flow cytometry analysis of keratinocyte (nHEK) transfection reactions
using three Amaxa Nucleofector II programs. (A) Untransfected control keratinocytes
show essentially no fluorescence. (B) Electroporation of keratinocytes with GFP mRNA
compared with GFP DNA plasmid with fraction of GFP-expressing cells shown;
GM=Geometric Mean; nHEK=neonatal Human Epidermal Keratinocytes; GFP=Green
Fluorescent Protein..
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Figure 2. Immunoblots of neonatal human foreskin fibroblasts (nHFF) transfected
with mRNA as shown. (A) First lane: untransfected nHFF; second lane: nHFF
transfected with OCT4 mRNA transcripts. (B) First lane: untransfected nHFF; second
lane: nHFF transfected with SOX2 mRNA transcripts. (A) First lane: untransfected
nHFF; second lane: nHFF transfected with KLF4 mRNA transcripts. (A) First lane:
untransfected nHFF; second lane: Jurkat cells as positive control; third lane: nHFF
transfected with c-MYC mRNA transcripts. Samples were standardized either by cell
counts (A-C) or direct protein quantitation (75 µg in each lane of gel pictured in D).
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Figure 3. Neonatal human epidermal keratinocyes (nHEK) infected with four
retroviruses containing reprogramming factors OCT4, SOX2, KLF4, and c-MYC.
(A) Flow cytometry data for nHEK cells individually infected with retroviruses
containing one of the four reprogramming factors. (B) Infected nHEK cells infected with
all four reprogramming factors, three days post-infection at 100x magnification; (C)
nHEK cells from (B) under UV microscopy and displaying production of GFP marker,
confirming transgene expression; (D) Representative colony stained by alkaline
phosphatase assay. nHEK=neonatal Human Epidermal Keratinocytes.
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Figure 4. Representative morphology of transformed cell colonies 7 days posttransfection. (A) Representative colonies of human embryonic stem cells (hES H1 P60)
grown on iMEF feeder layer pictured here for morphologic comparison; (B)
Representative colony of transformed nHEK cells at day 7 post-transfection with no VPA
exposure; (C) Control well seeded with untransfected nHEK cells and exposed to the
same culture conditions (no VPA) as cells in (B); (D) (B) Representative colony of
transformed nHEK cells at day 7 post-transfection with 3 days of VPA exposure; (E)
Control well seeded with untransfected nHEK cells and exposed to the same culture
conditions (3 days in VPA) as cells in (D).
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Figure 5. Immunoblot analyses of neonatal human foreskin fibroblasts (nHFF)
transfected with mRNA as shown. (A) First lane: untransfected nHFF; second lane:
nHFF transfected with NANOG mRNA transcripts. (B) First lane: untransfected nHFF;
second lane: nHFF transfected with P53DD mRNA transcripts.

39
A
B
C
se
co
nd
lan
e:
se
co
nd
Figure
lan 6. Alkaline phosphatase activity of human embryonic stem cells and
e:
transfected human keratinocytes (A) Representative colonies of human embryonic
stem cells (hES H1 P60) grown on matrigel and stained for alkaline phosphatase activity;
(B-C) Two small round cells produced from electroporation of five transcription factors
(OCT4, SOX2, KLF4, c-MYC, and NANOG) into neonatal human epidermal
keratinocytes demonstrating alkaline phosphatase activity at day 16 post transfection.
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Figure 7. Keratinocyte viability after electroporation with increasing concentrations
of GFP mRNA. (A) Cell counts 18 hours post-transfection show decreasing viability
relative to increasing mRNA concentration used in transfection. Starting amount was
approximately 2 x106 cells in each transfection. (B) Flow cytometry data showing
showing increasing mean fluorescence with increasing mRNA concentration. A lowfluorescing population of cells make up a more significant percentage of cell population
in the high-concentration mRNA transfection sample. nHEK=neonatal Human Epidermal
Keratinocytes.

41
REFERENCES

1. Thomson J, Itskovitz-Eldor J, Shapiro S, Waknitz M, Swiergiel J, Marshall V, Jones J.
Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282 (5391):
1145–7.
2. Lindvall O (2003). Stem cells for cell therapy in Parkinson's disease. Pharmacol Res
47 (4): 279–87.
3. Goldman S, Windrem M. Cell replacement therapy in neurological disease. Philos
Trans R Soc Lond B Biol Sci . 2006; 361 (1473): 1463–75.
4. Kaufman DS, Thomson JA. Human ES cells—haematopoiesis and transplantation
strategies. J Anat. 2002 Mar; 200(Pt 3):243-8.
5. Boheler KR, Czyz J, Tweedie D, Yang HT, Anisimov SV, Wobus AM. Differentiation
of pluripotent embryonic stem cells into cardiomyocytes. Circ Res. 2002 Aug
9;91(3):189-201.
6. Chidgey AP, Layton D, Trounson A, Boyd RL. Tolerance strategies for stem cellbased therapies. Nature. 2008 May 15;453(7193):330-7.
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic
and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76.
8. Wakayama T, Perry AC, Zuccotti M, Johnson KR, Yanagimachi R. Full-term
development of mice from enucleated oocytes injected with cumulus cell nuclei. Nature.
1998 Jul 23;394(6691):369-74
9. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived
from fetal and adult mammalian cells. Nature. 1997 Feb 27;385(6619):810-3.
10. Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells
after fusion with human embryonic stem cells. Science. 2005 Aug 26;309(5739):1369-73.
11. Tada M, Morizane A, Kimura H, Kawasaki H, Ainscough JF, Sasai Y, Nakatsuji N,
Tada T. Pluripotency of reprogrammed somatic genomes in embryonic stem hybrid cells.
Dev Dyn. 2003 Aug;227(4):504-10.
12. Kanatsu-Shinohara M, Inoue K, Lee J, Yoshimoto M, Ogonuki N, Miki H, Baba S,
Kato T, Kazuki Y, Toyokuni S, Toyoshima M, Niwa O, Oshimura M, Heike T, Nakahata
T, Ishino F, Ogura A, Shinohara T. Generation of pluripotent stem cells from neonatal
mouse testis. Cell. 2004 Dec 29;119(7):1001-12.
13. Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L, Bonin M, Aicher W,
Bühring HJ, Mattheus U, Mack A, Wagner HJ, Minger S, Matzkies M, Reppel M,

42

Hescheler J, Sievert KD, Stenzl A, Skutella T. Generation of pluripotent stem cells from
adult human testis. Nature. 2008 Nov 20;456(7220):344-9.
14. Meissner A, Jaenisch R. Mammalian nuclear transfer. Dev Dyn. 2006
Sep;235(9):2460-9.
15. Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer
from a cultured cell line. Nature. 1996 Mar 7;380(6569):64-6
16. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear
reprogramming. Cell. 2008 Feb 22;132(4):567-82.
17. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J,
Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem
cell lines derived from human somatic cells. Science. 2007 Dec 21;318(5858):1917-20.
18. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilić
J, Pekarik V, Tiscornia G, Edel M, Boué S, Izpisúa Belmonte JC. Efficient and rapid
generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol.
2008 Nov;26(11):1276-84.
19. Ye Z, Zhan H, Mali P, Dowey S, Williams DM, Jang YY, Dang CV, Spivak JL,
Moliterno AR, Cheng L. Human-induced pluripotent stem cells from blood cells of
healthy donors and patients with acquired blood disorders. Blood. 2009 Dec
24;114(27):5473-80.
20. Takenaka C, Nishishita N, Takada N, Jakt LM, Kawamata S. Effective generation of
iPS cells from CD34(+) cord blood cells by inhibition of p53. Exp Hematol.2009 Nov 14.
21. Tsai SY, Clavel C, Kim S, Ang YS, Grisanti L, Lee DF, Kelley K, Rendl M. Oct4
and Klf4 Reprogram Dermal Papilla Cells into Induced Pluripotent Stem Cells.
StemCells. . [Epub ahead of print]
22. Daley GQ, Lensch MW, Jaenisch R, Meissner A, Plath K, Yamanaka S. Broader
implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell. 2009
Mar 6;4(3):200-1
23. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced
pluripotent stem cells. Cell Stem Cell. 2008 Dec 4;3(6):595-605.
24. Smith KP, Luong MX, Stein GS. Pluripotency: toward a gold standard for human ES
and iPS cells. J Cell Physiol. 2009 Jul;220(1):21-9.
25. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, Kupriyanov
S, Baldwin KK. Adult mice generated from induced pluripotent stem cells. Nature. 2009
Sep 3;461(7260):91-4.

43

26. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, Song X, Guo Y, Zhao Y, Qin H, Yin
X, Wu C, Che J, Lu S, Ding M, Deng H. Efficient generation of hepatocyte-like cells
from human induced pluripotent stem cells. Cell Res. 2009 Nov;19(11):1233-42.
27. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation,
purification and transplantation of photoreceptors derived from human induced
pluripotent stem cells. PLoS One. 2010 Jan 20;5(1):e8763
28. Gai H, Leung EL, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma
Y. Generation and characterization of functional cardiomyocytes using induced
pluripotent stem cells derived from human fibroblasts. Cell Biol Int. 2009
Nov;33(11):1184-93.
29. Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH, Wagner EF,
Keller GM. Directed differentiation of hematopoietic precursors and functional
osteoclasts from human ES and iPS cells. Blood. 2010 Jan 11 [Epub ahead of print].
30. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A,
Cooper O, Mitalipova M, Isacson O, Jaenisch R. Parkinson's disease patient-derived
induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009 Mar
6;136(5):964-77
31. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft
GF, Saphier G, Leibel R, Goland R, Wichterle H, Henderson CE, Eggan K. Induced
pluripotent stem cells generated from patients with ALS can be differentiated into motor
neurons. Science. 2008 Aug 29;321(5893):1218-21.
32. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW,
Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem cells.
Cell. 2008 Sep 5;134(5):877-86. Epub 2008 Aug 7
33. Gunaseeli I, Doss MX, Antzelevitch C, Hescheler J, Sachinidis A. Induced
Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug
Discovery. Curr Med Chem. 2010 Jan 21. [Epub ahead of print]
34. Hawley RG. Does retroviral insertional mutagenesis play a role in the generation of
induced pluripotent stem cells? Mol Ther. 2008 Aug;16(8):1354-5.
35. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced
pluripotent stem cells. Nature. 2007 Jul 19;448(7151):313-7.
36. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem
cells generated without viral integration. Science. 2008 Nov 7;322(5903):945-9.
37. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA. Human
induced pluripotent stem cells free of vector and transgene sequences. Science. 2009 May
8;324(5928):797-801.

44

38. Chang CW, Lai YS, Pawlik KM, Liu K, Sun CW, Li C, Schoeb TR, Townes TM.
Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to
induced pluripotent stem cells. Stem Cells. 2009 May;27(5):1042-9.
39. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free
induction of pluripotency and subsequent excision of reprogramming factors. Nature.
2009 Apr 9;458(7239):771-5.
40. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling
R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A. piggyBac transposition
reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009 Apr
9;458(7239):766-70
41. Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E,
Weissman SM. Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther.
2006 Oct;17(10):1027-35.
42. Lowry WE, Plath K. The many ways to make an iPS cell. Nat Biotechnol. 2008
Nov;26(11):1246-8
43. Rabinovich PM, Komarovskaya ME, Wrzesinski SH, Alderman JL, Budak-Alpdogan
T, Karpikov A, Guo H, Flavell RA, Cheung NK, Weissman SM, Bahceci E. Chimeric
Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes. Hum
Gene Ther. 2008 Oct 15.
44. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A highefficiency system for the generation and study of human induced pluripotent stem cells.
Cell Stem Cell. 2008 Sep 11;3(3):340-5.
45. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, Hock H,
Hochedlinger K. Differentiation stage determines potential of hematopoietic cells for
reprogramming into induced pluripotent stem cells. Nat Genet. 2009 Sep;41(9):968-76.
46. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA.
Induction of pluripotent stem cells by defined factors is greatly improved by smallmolecule compounds. Nat Biotechnol. 2008 Jul;26(7):795-7
47. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W,
Melton DA. Induction of pluripotent stem cells from primary human fibroblasts with only
Oct4 and Sox2. Nat Biotechnol. 2008 Nov;26(11):1269-75.
48. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita
K,Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21
pathway. Nature. 2009 Aug 27;460(7259):1132-5

45

49. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM,
Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell
reprogramming. Nature. 2009 Aug 27;460(7259):1140-4. Epub 2009 Aug 9.
50. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden
A, Jaenisch R. Direct cell reprogramming is a stochastic process amenable to
acceleration. Nature. 2009 Dec 3;462(7273):595-601. Epub 2009 Nov 8.
51. Bowman T, Symonds H, Gu L, Yin C, Oren M, Van Dyke T. Tissue-specific
inactivation of p53 tumor suppression in the mouse. Genes Dev. 1996 Apr 1;10(7):82635.
52. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of human-induced
pluripotent stem cells. Nat Protoc. 2008;3(7):1180-6.
53. Page RL, Ambady S, Holmes WF, Vilner L, Kole D, Kashpur O, Huntress V, Vojtic
I, Whitton H, Dominko T. Induction of stem cell gene expression in adult human
fibroblasts without transgenes. Cloning Stem Cells. 2009 Sep;11(3):417-26.
54. Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V,
Mo Q, Studer L, Sadelain M. Stoichiometric and temporal requirements of Oct4, Sox2,
Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc
Natl Acad Sci U S A. 2009 Aug 4;106(31):12759-64.
55. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal
transforming domain of p53: negative dominance through abrogation of sequencespecific DNA binding. Mol Cell Biol. 1992 Dec;12(12):5581-92.
56. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, Song X, Guo Y, Zhao Y, Qin H, Yin
X, Wu C, Che J, Lu S, Ding M, Deng H. Efficient generation of hepatocyte-like cells
from human induced pluripotent stem cells. Cell Res. 2009 Nov;19(11):1233-42.
57. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation,
purification and transplantation of photoreceptors derived from human induced
pluripotent stem cells. PLoS One. 2010 Jan 20;5(1):e8763
58. Gai H, Leung EL, Costantino PD, Aguila JR, Nguyen DM, Fink LM, Ward DC, Ma
Y. Generation and characterization of functional cardiomyocytes using induced
pluripotent stem cells derived from human fibroblasts. Cell Biol Int. 2009
Nov;33(11):1184-93.
59. Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH, Wagner EF,
Keller GM. Directed differentiation of hematopoietic precursors and functional
osteoclasts from human ES and iPS cells. Blood. 2010 Jan 11 [Epub ahead of print].
60. Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K,
Yoshino T, Kazuki K, Ishihara C, Takehara S, Higaki K, Nakagawa M, Takahashi K,

46

Yamanaka S, Oshimura M. Complete Genetic Correction of iPS Cells From Duchenne
Muscular Dystrophy. Mol Ther. 2009 Dec 8.
61. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y. Phenotypic
correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U
S A. 2009 Jan 20;106(3):808-13.
62. Townes TM. Gene replacement therapy for sickle cell disease and other blood
disorders. Hematology Am Soc Hematol Educ Program. 2008:193-6.
63. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard
C,Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia mouse
model with iPS cells generated from autologous skin. Science. 2007
Dec21;318(5858):1920-3. Epub 2007 Dec 6.
64. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of
adult pancreatic exocrine cells to beta-cells. Nature. 2008 Oct 2;455(7213):627-32.
65. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y,
Siuzdak G, Schöler HR, Duan L, Ding S. Generation of induced pluripotent stem cells
using recombinant proteins. Cell Stem Cell. 2009 May 8;4(5):381-4.
66. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A,
Rheinwald JG, Hochedlinger K. Immortalization eliminates a roadblock during cellular
reprogramming into iPS cells. Nature. 2009 Aug 27;460(7259):1145-8.
67. Yang TA, Heiser WC, Sedivy JM. Efficient in situ electroporation of mammalian
cells grown on microporous membranes. Nucleic Acids Res. 1995 Aug 11;23(15):280310.
68. Deora AA, Diaz F, Schreiner R, Rodriguez-Boulan E. Efficient electroporation of
DNA and protein into confluent and differentiated epithelial cells in culture.Traffic. 2007
Oct;8(10):1304-12.
69. Zhao Y, Zheng Z, Cohen CJ, Gattinoni L, Palmer DC, Restifo NP, Rosenberg SA,
Morgan RA. High-efficiency transfection of primary human and mouse T lymphocytes
using RNA electroporation. Mol Ther. 2006 Jan;13(1):151-9.
70. Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Chen SL, Magun BE.
Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by
inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to
the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997 Jun;17(6):3373-81.
71. Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Magun BE. Ultraviolet
radiation triggers the ribotoxic stress response in mammalian cells. J Biol Chem. 1998
Jun 19;273(25):15794-803

47

72. Iordanov MS, Choi RJ, Ryabinina OP, Dinh TH, Bright RK, Magun BE. The UV
(Ribotoxic) stress response of human keratinocytes involves the unexpected uncoupling
of the Ras-extracellular signal-regulated kinase signaling cascade from the activated
epidermal growth factor receptor. Mol Cell Biol. 2002 Aug;22(15):5380-94.

